1551 EITHER INTRAGRAFT ADMINISTRATION OF ABCIXIMAB AND VERAPAMIL COMBINED

1073 EITHER CAT? PREVALENCE OF STREPTOCOCCUS A TONSILLITIS AND
1105 EITHER CAT 6 PREDICTORS AND OUTCOME OF HOSPITALIZED
1256 EITHER CAT PERCUTANEOUS CORONARY INTERVENTION EFFECT OF BASELINE

1356 EITHER CAT 19 SYSTEMIC NANOPARTICLE ALBUMINBOUND PACLITAXEL (ABI007)
1373 EITHER CAT 52 DOPPLER AND CATHTER GRADIENT DISCREPANCIES
1424 EITHER CAT 17 TREATMENT OF SAPHENOUS VEIN GRAFT

Intragraft Administration Of Abciximab And Verapamil Combined With Direct Stenting Prevents Slow-Flow And No-Reflow Phenomenon

1551, Either

INTRAGRAFT ADMINISTRATION OF ABCIXIMAB AND VERAPAMIL COMBINED WITH DIRECT STENTING PREVENTS SLOW-FLOW AND NO-REFLOW PHENOMENON IN SAPHENOUS VEIN GRAFT PERCUTANEOUS CORONARY INTERVENTION

S. Sharma, J.A. Lardizabal, A. Antonescu, B. Bhambi, W. Nyitray, K. Desai,

T. Ishimori

Bakersfield Heart Hospital, Central Cardiology, Bakersfield, CA, USA


Background: Slow flow/ no-reflow phenomenon (SF-NR) complicates up to 15% cases of percutaneous coronary intervention (PCI) in saphenous vein grafts (SVG). We hypothesized that a strategy of prophylactic intragraft administration of abciximab and verapamil into the SVG, combined with immediate direct stenting of the graft lesion without pre-dilatation, would reduce the risk of platelet activation, microvascular vasospasm and distal plaque embolization respectively and cause a reduction in the incidence of SF-NR.

Methods: Data from 130 consecutive patients who underwent PCI of SVG lesions in a single center over a 7-year period were reviewed. Patients who underwent conventional PCI technique (balloon pre-dilatation of the target lesion prior to stent deployment; optional use of intragraft verapamil or intravenous abciximab) were assigned to the control group (n=72). The patients who received prophylactic intragraft administration of abciximab (0.25 mg/kg) and verapamil (100-300 mcg, depending upon blood pressure and heart rate) through the guiding catheter followed by direct stenting were assigned to the novel strategy group (n=58). The primary outcome was the occurrence of SF-NR Clinical endpoints included death, MI, target vessel revascularization (TVR), and MACE during the hospitalization period, 30 days and at 1 year.

Results: SF-NR occurred more frequently in the control group compared to the novel strategy group (11% vs. 2%, P=0.04). One patient in the control group died after developing persistent SF-NR and acute MI post-PCI. No death was reported in the novel strategy group. Three patients, all in the control group, developed post-PCI MI during the index hospitalization. The difference in 30-day MI and TVR rates did not reach statistical significance. There was a non-statistically significant trend towards higher 1-year MI rate in the control group (8% vs. 2%; P=0.13). The control had significantly higher rates of MACE (25% vs. 7%, P=0.01) and TVR (22% vs. 7%, P=0.03) at 1 year as compared to the novel strategy group. 

Conclusions: In SVG PCI, the novel strategy of prophylactic intragraft administration of abciximab and verapamil, combined with direct stenting of the graft lesion without pre-dilatation, was associated with significantly lower rates of SF-NR compared with conventional PCI techniques.

 



1455 EITHER CAT 47 CONTINUOUS CATHETER IMPEDANCE MEASUREMENTS GUIDES
1526 EITHER CAT 58 A RETROSPECTIVE STUDY ON TRANSRADIAL
1546 EITHER CAT 25 THE EFFECTS OF ANTIHYPERTENSIVE DRUGS


Tags: abciximab and, of abciximab, combined, either, administration, intragraft, verapamil, abciximab